FDA approves ForDoz's generic doxil liposome injection
The drug is indicated for treatment of ovarian cancer, AIDS-related Kaposi’s Sarcoma and multiple myeloma.
Lupin’s alliance partner, ForDoz has received approval from the Food and Drug Administration for doxorubicin hydrochloride liposome injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, which is a generic of Baxter Healthcare’s doxil liposome injection.
The medication is indicated for treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.
[Read more: Lupin receives FDA OK for generic Banzel]
doxorubicin hydrochloride liposome injection had a market value of roughly $42 million per IQVIA May 2024 data.
[Read more: Lupin receives FDA nod for 3 generics]